LONG BEACH, Calif. / Sep 09, 2024 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) (“Molina” or the “Company”) today announced it will issue its earnings release for the third quarter ending September 30, 2024, after the market closes on Wednesday, October 23, 2024, and will host a conference call and webcast to discuss the earnings release on Thursday, October 24, 2024, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 7014206. A telephonic replay of the conference call will be available through Thursday, October 31, 2024, by dialing (877) 344-7529 and entering the confirmation number, 5232318.
A live broadcast of Molina Healthcare’s conference call will be available on the Company’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available shortly following the conclusion of the live broadcast.
2024 Investor Day
The Company also announced it will host its 2024 Investor Day meeting on Friday, November 8, 2024, in New York City. The publicly webcast event will begin at 9:30 a.m. Eastern Time.
In-person attendance is by invitation only. All others are invited to register for the event on the Company’s investor relations website at investors.molinahealthcare.com, or directly via the following link: Molina Investor Day Meeting 2024. A 30-day online replay of the Investor Day meeting will be available shortly following the conclusion of the live webcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit MolinaHealthcare.com.
Last Trade: | US$351.20 |
Daily Change: | -3.95 -1.11 |
Daily Volume: | 104,992 |
Market Cap: | US$20.580B |
July 23, 2024 July 19, 2024 April 11, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB